Krugman S, Holley H P, Davidson M, Simberkoff M S, Matsaniotis N
J Med Virol. 1981;8(2):119-21. doi: 10.1002/jmv.1890080205.
The immunogenic effect of inactivated hepatitis B vaccine (Merck Heptavax B) was evaluated in 202 seronegative healthy medical personnel. Three inoculations of vaccine were given at 1-month intervals. Of 116 vaccinees who received a 40-microgram dose, 39% had an anti-HBs response 1 month after the first dose, 88% 1 month after the second dose, and 99% 1 month after the third dose. Of 86 vaccinees who received a 20 microgram dose, 40% had an anti-HBs response 1 month after the first dose, 79% after the second dose, and 95% after the third dose. These results confirm the high immunogenic effect of a 20-microgram dose of vaccine.
在202名血清学阴性的健康医护人员中评估了灭活乙肝疫苗（默克公司的Heptavax B）的免疫原性。疫苗分三次接种，间隔1个月。在接受40微克剂量的116名接种者中，39%在首剂接种后1个月出现抗-HBs反应，88%在第二剂接种后1个月出现，99%在第三剂接种后1个月出现。在接受20微克剂量的86名接种者中，40%在首剂接种后1个月出现抗-HBs反应，79%在第二剂接种后出现，95%在第三剂接种后出现。这些结果证实了20微克剂量疫苗具有高免疫原性。
